← All trials
NCT04522466
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 3, 2020
- Primary completion
- May 28, 2020
- Completion date
- May 28, 2020
- First posted
- Aug 21, 2020
- Last posted
- Sep 7, 2020
- Enrollment
- 7
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of LyonLead sponsor
- University of LyonOverall official - principal investigator
- Centre Etienne Dolet SAINT NAZAIRE FranceCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.